RELAPSING REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests how the drug ocrelizumab works in children and teens (ages 10 to under 18) with relapsing-remitting multiple sclerosis. It measures drug levels, safety, and immune effects over 48 weeks, with optional longer follow-up. The goal is to control the disease, not cure…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Double-Drug strike aims to halt MS early
Disease control Not yet recruitingThis study tests whether giving two strong medications one after the other can safely control relapsing-remitting multiple sclerosis (MS) in its early stages. Sixty adults aged 18-50 with active MS will receive rituximab infusions followed by cladribine tablets, then be monitored…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Uppsala University • Aim: Disease control
Last updated May 11, 2026 20:52 UTC